Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RxSight, Inc.
Report date August 03, 2021 · Filed August 05, 2021
Section 16 reporting ended · disclosed 2021-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 407,647 |
Reported balance
After 2021-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-08-03 · Conversion · Acquired 3,969 · Balance 407,647 F1: All shares of the Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-1.0251 basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: The number of shares reported as beneficially held by the Reporting Person in the Form 3 filed July 29, 2021 incorrectly overstated the number of shares held by 11,012 shares. The correct number of shares should have been reported as 403,678. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-03 · Conversion · Disposed 3,872 · Balance 0 F1: All shares of the Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-1.0251 basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of the Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-1.0251 basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F2: The number of shares reported as beneficially held by the Reporting Person in the Form 3 filed July 29, 2021 incorrectly overstated the number of shares held by 11,012 shares. The correct number of shares should have been reported as 403,678.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2021 Filed Aug 5, 2021 23:49 UTC | RxSight, Inc. RXST · Entity 1226 | ConversionSeries C Preferred Stock · Derivative | 3,872 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031831 · doc4.xml · derivative · entry 2 Schwartz Daniel Mark · CIK 0001874073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All shares of the Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-1.0251 basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · price: All shares of the Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-1.0251 basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: All shares of the Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-1.0251 basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: All shares of the Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-1.0251 basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:49 UTC | RxSight, Inc. RXST · Entity 1226 | ConversionCommon Stock | 3,969 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031831 · doc4.xml · nonDerivative · entry 1 Schwartz Daniel Mark · CIK 0001874073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All shares of the Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-1.0251 basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · balance_after: The number of shares reported as beneficially held by the Reporting Person in the Form 3 filed July 29, 2021 incorrectly overstated the number of shares held by 11,012 shares. The correct number of shares should have been reported as 403,678. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.